LIF anticorps (N-Term)
-
- Antigène Voir toutes LIF Anticorps
- LIF (Leukemia Inhibitory Factor (LIF))
-
Épitope
- N-Term
-
Reactivité
- Humain, Souris, Rat, Boeuf (Vache), Chien, Mouton, Cheval, Cobaye, Lapin
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp LIF est non-conjugé
-
Application
- Western Blotting (WB)
- Séquence
- KVLAAGVVPL LLVLHWKHGA GSPLPITPVN ATCAIRHPCH NNLMNQIRSQ
- Homologie
- Cow: 100%, Dog: 100%, Guinea Pig: 100%, Horse: 100%, Human: 100%, Mouse: 100%, Rabbit: 86%, Rat: 100%, Sheep: 86%
- Attributs du produit
- This is a rabbit polyclonal antibody against LIF. It was validated on Western Blot using a cell lysate as a positive control.
- Purification
- Affinity Purified
- Immunogène
- The immunogen is a synthetic peptide directed towards the N terminal region of human LIF
- Top Product
- Discover our top product LIF Anticorps primaire
-
-
- Indications d'application
- Optimal working dilutions should be determined experimentally by the investigator.
- Commentaires
-
Antigen size: 202 AA
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- Lot specific
- Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma." dans: Cancer, Vol. 113, Issue 3, pp. 490-6, (2008) (PubMed).
: "
-
Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma." dans: Cancer, Vol. 113, Issue 3, pp. 490-6, (2008) (PubMed).
-
- Antigène
- LIF (Leukemia Inhibitory Factor (LIF))
- Autre désignation
- LIF (LIF Produits)
- Synonymes
- anticorps CDF, anticorps DIA, anticorps HILDA, anticorps MLPLI, anticorps LIF, interleukin 6 family cytokine, anticorps leukemia inhibitory factor, anticorps LIF, anticorps Lif
- Sujet
-
LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface.Leukaemia inhibitory factor is a cytokine that induces macrophage differentiation. Neurotransmitters and neuropeptides, well known for their role in the communication between neurons, are also capable of activating monocytes and macrophages and inducing chemotaxis in immune cells. LIF signals through different receptors and transcription factors. LIF in conjunction with BMP2 acts in synergy on primary fetal neural progenitor cells to induce astrocytes. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.
Alias Symbols: CDF, D-FACTOR, HILDA, DIA
Protein Interaction Partner: IL6ST, LIFR,
Protein Size: 202 - Poids moléculaire
- 22 kDa
- ID gène
- 3976
- NCBI Accession
- NM_002309, NP_002300
- UniProt
- P15018
- Pathways
- Signalistation JAK/STAT, Positive Regulation of Peptide Hormone Secretion, Negative Regulation of Hormone Secretion, Stem Cell Maintenance, Growth Factor Binding
-